Annovis Bio announced completion of data cleaning for its Phase III study of buntanetap in patients with early Parkinson’s disease. Topline efficacy data is expected in June. The Phase III study was completed in 4Q 2023 with an original plan for data announcement in 1Q 2024, however the company faced a delay in the process of data cleaning beyond the original prognosis.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANVS:
Questions or Comments about the article? Write to editor@tipranks.com